

Fig. S1




Fig. S1 The effect of paclitaxel on subcellular localization of PD-L1.

a Left, immunostaining of PD-L1 (green) and Calnexin-labeled endoplasmic reticulum (red) in TNBC cells with or without 20 nM paclitaxel treatment for 12 h in TNBC cells. Scale bars, 20 μ m and 2 μ m (inset). Right, the percentage of PD-L1 co-localized with Calnexin ($n = 5$ fields, t -test). **b** Left, immunostaining of PD-L1 (green) and TGN46-labeled Golgi complex (red) with or without 20 nM paclitaxel treatment for 12 h in TNBC cells. Scale bars, 20 μ m and 2 μ m (inset). Right, the percentage of PD-L1 co-localized with TGN46 ($n = 5$ fields, t -test). **c** Left, immunostaining of PD-L1 (green) and TOM20-labeled mitochondria (red) with or without 20 nM paclitaxel treatment for 12 h in MDA-MB-468 cells. Scale bars, 20

μm and $2 \mu\text{m}$ (inset). Right, the percentage of PD-L1 co-localized with TOM20 ($n = 5$ fields, t -test). Data are representative of at least two independent experiments and are shown as means \pm SD.